FDA approves pirtobrutinib for untreated CLL or SLL
The approval covers adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma who lack a 17p deletion.
The Food and Drug Administration approved pirtobrutinib, sold as Jaypirca by Eli Lilly and Company, on October 2, 2026. The approval covers adult patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) with no known 17p deletion.1
The document provided does not include additional details on the clinical trial data, dosing information, or efficacy endpoints that supported this approval. Readers seeking those specifics should consult the full FDA prescribing information or Eli Lilly's company statements for further details.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.